Goodwin Biotechnology, Inc (Florida, US), a fully-owned subsidiary of Goa-based Wallace Pharmaceuticals, is keen to offer contract manufacturing services to Indian biopharmaceutical companies.
Karl Pinto, chairman, Goodwin Biotechnology, Inc (GBI) and Wallace, USA said, in the US, the company is extending its GMP mammalian cell culture capabilities by deploying a 500L stirred tank train (including multiple smaller tanks) with variable working volume capacities. This will be completed by the third quarter of 2006.
The company is looking at the possibility of partnering with bio-pharma companies of India for contract manufacturing. We see India as a tremendous resource for us, both on the 'buy' side as well as the 'sell' side of our business, Karl Pinto said.
India is extremely competitive in the small molecule generics market due to robust global regulations relating to generics, but unfortunately biologics is still far behind as far as this is concerned due to the reluctance of the US FDA and the EMEA to use similar paradigms, Pinto added.